Zacks Research Issues Pessimistic Outlook for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at Zacks Research reduced their Q1 2027 EPS estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, July 1st. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.42 for the quarter, down from their prior forecast of $0.43. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

AXSM has been the subject of several other research reports. Jefferies Financial Group initiated coverage on Axsome Therapeutics in a research report on Monday, April 7th. They issued a “buy” rating and a $200.00 price target for the company. Cantor Fitzgerald upgraded Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. Needham & Company LLC decreased their price target on Axsome Therapeutics from $153.00 to $150.00 and set a “buy” rating on the stock in a report on Monday, June 9th. HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, June 10th. Finally, Oppenheimer assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, June 3rd. They set an “outperform” rating and a $185.00 price objective for the company. One investment analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Axsome Therapeutics presently has an average rating of “Buy” and a consensus price target of $172.33.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $105.36 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. Axsome Therapeutics has a twelve month low of $72.21 and a twelve month high of $139.13. The company’s 50-day moving average price is $106.65 and its 200-day moving average price is $107.48. The company has a market cap of $5.19 billion, a PE ratio of -18.26 and a beta of 0.46.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. boosted its holdings in shares of Axsome Therapeutics by 16,852.7% in the first quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company’s stock valued at $73,176,000 after purchasing an additional 623,717 shares during the period. Boxer Capital Management LLC bought a new stake in Axsome Therapeutics during the 4th quarter valued at $39,767,000. Lazard Asset Management LLC lifted its holdings in shares of Axsome Therapeutics by 525.7% in the 4th quarter. Lazard Asset Management LLC now owns 537,669 shares of the company’s stock worth $45,492,000 after buying an additional 451,737 shares during the period. Nuveen LLC purchased a new stake in shares of Axsome Therapeutics in the 1st quarter worth $48,185,000. Finally, Norges Bank bought a new position in shares of Axsome Therapeutics during the 4th quarter worth $34,100,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Mark L. Jacobson sold 25,000 shares of Axsome Therapeutics stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the completion of the sale, the chief operating officer owned 5,783 shares in the company, valued at $638,674.52. This trade represents a 81.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Hunter R. Murdock sold 6,014 shares of the business’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $100.12, for a total transaction of $602,121.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 93,437 shares of company stock valued at $9,834,215. 22.30% of the stock is currently owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.